Clinical trials: Malignant Tumor
Non Small Cell Lung Cancer, Advanced Solid Tumor
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
- Trial name
- NCT06484816
- Testing
- TGRX-1942
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Unspecified Childhood Solid Tumor, Protocol Specific
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combining carboplatin and irinotecan in treating…
- Trial name
- NCT00024284
- Testing
- carboplatin, irinotecan hydrochloride
- Where
- 7 sites in United States, Canada
- Sponsor
- Bristol-Myers Squibb
Neoplasms, Neoplasms, Glandular and Epithelial
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK)…
- Conditions
- Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms
- Trial name
- NCT02909452
- Testing
- Entinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Neoplasms
A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.
This study will determine the maximum tolerated dose and the dose limiting toxicities (Part 1 of study) and the activity (Part 2 of study) of RO5126766 in patients with metastatic or advanced solid tumors.
- Trial name
- NCT00773526
- Testing
- RO5126766
- Where
- 3 sites in France, Spain and 1 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Merkel Cell
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in participants with metastatic Merkel cell carcinoma (MCC).
- Trial name
- NCT02155647
- Testing
- Avelumab
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 204 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Merkel Cell Carcinoma
IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
This phase II trial studies the effectiveness of ImmunoPulse IL-12® in treating patients with Merkel cell cancer. ImmunoPulse IL-12® is the combination of intratumoral interleukin-12 gene (also known as tavokinogene telseplasmid…
- Trial name
- MCC (NCT01440816)
- Testing
- Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- OncoSec Medical Incorporated
Advanced Malignant Solid Tumors
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
This study is an open-label, multicenter, dose-escalation and dose-expansion Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of AK150…
- Trial name
- NCT07566247
- Testing
- AK150
- Where
- 3 sites in China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Akeso
Solid Tumor, Adult, Solid Tumor
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
This clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06075849
- Testing
- PB101
- Where
- 3 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Panolos Bioscience
Desmoplastic Small Round Cell Tumor
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children…
- Trial name
- NCT04145349
- Testing
- Ramucirumab, Cyclophosphamide, Vinorelbine
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Castrate Resistant Prostate Cancer
Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients
The study has three parts. Part 1 is a dose escalation to investigate the safety and tolerability of ASP9521. Part 2 will evaluate the safety and tolerability and initial anti-tumor activity of ASP9521.
- Trial name
- NCT01352208
- Testing
- ASP9521
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 13 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
The primary objective of this study is to evaluate the efficacy of andecaliximab (GS-5745) versus placebo as an add-on therapy to a tumor necrosis factor (TNF) inhibitor and methotrexate in adults with moderate to severe…
- Trial name
- NCT02862574
- Testing
- Andecaliximab, Methotrexate, TNF Inhibitor
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Gilead Sciences
Gastroenteropancreatic Neuroendocrine Tumor
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
- Trial name
- NCT03017690
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ipsen
3rd Line GIST
A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
The purpose of this study is to determine a maximum tolerated dose and/or recommended phase 2 dose of a combination of imatinib and BYL719 in the treatment of 3rd line GIST patients.
- Trial name
- NCT01735968
- Testing
- ST571 + BYL719
- Where
- 11 sites in United States, Belgium and 6 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin's Lymphoma
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101 (RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma.
- Trial name
- NCT00576758
- Testing
- obinutuzumab (RO5072759), rituximab
- Where
- 71 sites in United States, Argentina and 15 more
- Volunteers
- 175 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT…
- Trial name
- GLORIA (NCT04121455)
- Testing
- Olaptesed pegol, Radiotherapy, Bevacizumab
- Where
- 6 sites in Germany
- Volunteers
- 117 people
- Sponsor
- TME Pharma AG
Pancreatic Ductal Adenocarcinoma (PDAC)
OSCAR I STUDY - The ONCObind CTC Removal Study
This study is a Prospective Single Arm Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in metastatic PDAC refractory to systemic…
- Trial name
- NCT06481397
- Testing
- ONCObind (Onco-Seraph) 100 Filter
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- ExThera Medical Corporation
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
This 2 arm study will compare the efficacy and safety of Tarceva plus Avastin, and chemotherapy plus Avastin, in the first-line treatment of patients with advanced non-small cell lung cancer.
- Trial name
- NCT00531960
- Testing
- Erlotinib, Bevacizumab, Standard platinum-based chemotherapy
- Where
- 57 sites in Australia, Belgium and 11 more
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.